Abstracts tagged "neurologic involvement and pediatric rheumatology"

Abstract Number: 26 • 2017 Pediatric Rheumatology Symposium
Gray Matter Volume Loss in Youth with SLE
Andrea Knight¹, Michelle Vickery², Arastoo Vossough³, Guray Erus⁴, Jimit Doshi⁵ and Susan Furth⁶, ¹Center for Pediatric Clinical Effectiveness & PolicyLab, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Section on Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁵Section of Biomedical Image Analysis, University of Pennsylvania, Philadelphia, PA, ⁶Division of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neuropsychiatric SLE in children and adolescents presents diagnostic challenge due to limitations of conventional magnetic resonance imaging (MRI) to detect clinically relevant brain changes.…
Abstract Number: 3207 • 2016 ACR/ARHP Annual Meeting
The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke
Amanda K. Ombrello¹, Karyl Barron², Patrycja Hoffmann¹, Camilo Toro³, Deborah L. Stone⁴, Gineth Pinto-Patarroyo⁴, Anne Jones⁴, Tina Romeo⁵, Ariane Soldatos⁶, Qing Zhou⁷, Natalie Deuitch⁵, Jing Qin², Ivona Aksentijevich⁴ and Daniel L. Kastner⁴, ¹Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁶National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁷Inflammatory Disease Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resulting from biallelic mutations in CECR1. Patients commonly present with vascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].